Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
10 10월 2023 - 8:00PM
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company focused on developing innovative
treatments for cancer patients, today announced that Andrew J.
Cittadine, Monopar’s Chief Operating Officer, will present at the
Roth MKM 2023 Healthcare Opportunities Conference.
Presentation Details:
Date: October 12, 2023Time: 12:15 p.m. (ET)Location: The Yale
Club, New York City, New York
https://www.roth.com/conferences/upcoming-conferences
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical
company focused on developing innovative treatments for cancer
patients. Monopar's pipeline consists of camsirubicin (Phase 1b)
for the treatment of advanced soft tissue sarcoma; MNPR-101, a
late-stage preclinical antibody for radiopharmaceutical use in
advanced cancers; and MNPR-202, an early-stage camsirubicin analog
for various cancers. For more information,
visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc.Investor RelationsKim
R. TsuchimotoChief Financial Officerkimtsu@monopartx.com
Follow Monopar on social media for updates:Twitter:
@MonoparTx LinkedIn: Monopar Therapeutics
Monopar Therapeutics (NASDAQ:MNPR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Monopar Therapeutics (NASDAQ:MNPR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
